Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s ...
J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA ...
The Financial Express1 天
Cobenfy set to break dopamine dominance in schizophrenia treatment
According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...
Dry Powder Inhaler Market Set for Steady Growth Through 2034 | Future Market Insights, Inc.
Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and ...
IFLScience on MSN6 天
Newly Approved Schizophrenia Drug Could Eventually Treat Alzheimer’s-Related Psychosis
A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...